FDA grants Accelerated Approval for BMY’s Opdivo in second/third-line locally-advanced/metastatic melanoma: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm The PDUFA date was 3/30/15, so this FDA review was fast.